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ABSTRACT
Objective: To determine whether previous insulin treatment independently influences subse-
quent outcomes in diabetic patients with ACS (acute coronary syndromes). Subjects and me-
thods: 375 diabetic patients with ACS, divided in 2 groups: Group A (n = 69) – previous insulin 
and Group B (n = 306) – without previous insulin. Predictors of 1-year mortality and major 
adverse cardiac events (MACE) were analyzed by Cox regression analysis. Results: Group A 
had more previous stroke (17.4% vs. 9.2%, p = 0.047) and peripheral artery disease (13.0% vs. 
3.6%, p = 0.005). They had significantly higher admission glycemia and lower LDL cholesterol. 
There were no significant differences in the type of ACS, in 1-year mortality (18.2% vs. 10.4%, 
p = 0.103) or MACE (32.1% vs. 23.0%, p = 0.146) between groups. In multivariate analysis, insulin 
treatment was neither an independent predictor of 1-year mortality nor of MACE. Conclusion: 
Despite the more advanced atherosclerotic disease, diabetics under insulin had similar outco-
mes to those without insulin. Insulin may protect diabetics from the expected poor adverse 
outcome of an advanced atherosclerotic disease. Arq Bras Endocrinol Metab. 2010;54(7):612-9
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RESUMO 
Objectivo: Avaliar se a insulinoterapia prévia influencia de forma independente o prognóstico de 
diabéticos após uma síndrome coronária aguda (SCA). Sujeitos e métodos: 375 doentes diabéti-
cos com SCA, divididos em 2 grupos: Grupo A (n = 69) – sob insulinoterapia prévia e Grupo B (n = 
306) – sem insulinoterapia prévia. Os preditores de mortalidade a um ano e de eventos cardíacos 
adversos maiores (MACE) foram determinados pela regressão de Cox. Resultados: Verificou-se 
maior proporção de acidente vascular cerebral prévio (17,4% vs. 9,2%, p = 0,047) e doença arte-
rial periférica (13,0% vs. 3,6%, p = 0,005) no Grupo A. Esses doentes apresentaram glicemia na 
admissão significativamente mais elevada e LDL inferior. Não houve diferenças estatisticamente 
significativas no tipo de SCA, na mortalidade (18,2% vs. 10,4%, p = 0,103) e MACE (32,1% vs. 
23,0%, p = 0,146) em um ano entre os 2 grupos. Na análise multivariada, a insulinoterapia prévia 
não foi preditor independente nem de mortalidade, nem de MACE em 1 ano. Conclusão: Apesar 
da doença aterosclerótica mais avançada, os diabéticos previamente insulino-tratados têm um 
prognóstico semelhante aos não insulino-tratados. A insulinoterapia crônica poderá proteger os 
diabéticos da evolução desfavorável própria da doença aterosclerótica avançada. Arq Bras Endocrinol 
Metab. 2010;54(7):612-9  
Descritores






















613Arq Bras Endocrinol Metab. 2010;54/7
Insulin and acute coronary syndromes
INTRODUCTION
Despite significant advances in the treatment of di-abetic patients with Acute Coronary Syndromes 
(ACS), their prognosis remains worse than that of non-
diabetics (1,2). 
The risk of developing coronary artery disease 
(CAD) in diabetics is two to four times greater than 
that of non-diabetics, and diabetics with no history of 
previous myocardial infarction (MI) have the same risk 
of future cardiovascular events as non-diabetics who 
have suffered a previous heart attack (3,4). These re-
sults led the “Adult Treatment Panel III of the Natio-
nal Cholesterol Education Program” to establish diabe-
tes mellitus (DM) as a CAD risk equivalent, mandating 
aggressive anti-atherosclerotic treatment (5).
The metabolic abnormalities caused by DM induce 
endothelial dysfunction.  Among those abnormalities 
chronic hyperglycemia, dyslipidemia and insulin resis-
tance appear to be the most relevant. The progression 
of insulin resistance to diabetes parallels the progres-
sion of endothelial dysfunction to atherosclerosis (6).
Previous studies have shown that diabetic patients 
under chronic insulin therapy have a poorer prognosis 
after percutaneous coronary intervention (PCI) than 
non-insulin-treated diabetics (7-9). In the context of 
heart failure, prior insulin therapy also seems to be asso-
ciated with increased 1-year mortality (10). However, it 
is unknown whether this represents an effect of insulin 
itself or the need for insulin is only a marker of a more 
advanced form of the disease.
Despite the high prevalence of diabetes in ACS pa-
tients, there are no studies in the literature addressing 
the impact of prior insulin therapy on the prognosis of 
diabetic patients after an ACS.
The main objectives of this work were to compa-
re demographic and clinical characteristics, therapeutic 
approaches and clinical outcomes after an ACS between 
diabetics previously treated with insulin and non-insu-
lin-treated diabetics, and to verify whether prior insulin 
therapy independently influences the prognosis of dia-
betic patients after an ACS. 
SUBJECTS AND METHODS
Study design
This is a prospective, observational study (prospective 
data collection with a retrospective analysis of results) 
of 375 patients with previously known DM or newly 
diagnosed DM, consecutively admitted into a single in-
tensive coronary care unit for ACS, between May 2004 
and December 2006. 
All patients without previously known diabetes 
underwent an Oral Glucose Tolerance Test (OGTT) 
on the 4th or 5th day of hospitalization. The diagnosis 
of new DM was established on the 4th or 5th day of 
hospitalization in patients without previously known 
diabetes and fasting blood glucose levels equal to or 
greater than 126 mg/dL, or whose OGTT revealed a 
blood glucose level equal to or greater than 200 mg/dL 
two hours after the administration of 75 grams of glu-
cose (11).
We proceeded to the analysis of a database with 
standardized records made during the patient’s hos-
pitalization, which includes: demographic, clinical, 
electrocardiographic and laboratorial data, medication 
(previous, at admission and at discharge), type of ACS, 
in-hospital complications (including ventricular fibrilla-
tion, cardiogenic shock, cardiac arrest, recurrent MI 
and acute pulmonary edema), length of hospital stay 
and patient destination after discharge.
These patients underwent a one year follow-up. The 
occurrence of unplanned revascularization, re-infarc-
tion, cerebrovascular accident (CVA) and death from 
any cause was recorded.
We also analyzed the combined endpoint of cardio-
vascular death, myocardial nonfatal re-hospitalization 
for UA or MI and unplanned PCI during the first year 
– MACE (Major Adverse Cardiac Events). 
The study population was divided into two groups 
according to the previous use (Group A, n = 69) or not 
(Group B, n = 306) of insulin.
This investigation conforms to the principles outli-
ned in the Declaration of Helsinki, was approved by the 
Ethical Committee of Clinical Research of the Coimbra 
University Hospital, and written informed consent was 
obtained from all patients.
Statistical analysis
Continuous variables are presented as mean ± stan-
dard deviation (SD). Student’s t test or Mann-Whitney 
test were used for comparison of the two subgroups, 
according to whether the variables had normal distri-
bution or not, respectively.  Categorical variables are 
expressed as frequencies and percentages and were 
analyzed by c2 test or Fisher’s exact test. A p value 
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Multivariate analysis using the Cox regression model 
was performed to assess the independent effect of prior 
insulin therapy in the incidence of MACE and morta-
lity at one year. Predetermined (in univariate analysis) 
or clinically relevant variables were entered into these 
multivariable regression models. The impact of prior 
insulin therapy on one-year survival and MACE-free 
survival was evaluated by Kaplan-Meier analysis.
RESULTS
General characterization of the study population
Of the 375 patients included in the study, 252 (67.2%) 
were male, and the mean age was 70.0 ± 10.0 years.   
Regarding the type of ACS, 55 patients (14.7%) had Uns-
table Angina (UA), 205 (54.7%) non ST segment eleva-
tion myocardial infarction (NSTEMI) and 115 (30.6%) 
ST segment elevation myocardial infarction (STEMI).
Regarding cardiovascular risk factors, 84.8% of pa-
tients had a history of hypertension, 84.7% hyperlipi-
demia and 10.2% had smoking habits. With respect to 
past medical history, 23.5% of patients had prior MI, 
and history of heart failure and of stroke or transient is-
chemic attack (TIA) was present in 2.5% and 10.7%, 
respectively. Newly diagnosed diabetes was found in 
30% of all patients.
Regarding the electrocardiographic and hemody-
namic data on admission, 78.0% of patients presented 
with Killip class I, 86.1% were in sinus rhythm (SR) 
and 11.5% in atrial fibrillation (AF) in the first elec-
trocardiogram (ECG) performed after hospital admis-
sion, and 2.7% of patients had left bundle branch block 
(LBBB).  The mean blood glucose level at admission 
was 137.0 ± 65 mg/dL.
Comparison of previously insulin-treated and  
non-insulin-treated diabetics
Concerning the comparison between the two groups, 
previously insulin-treated diabetics had a higher preva-
lence of peripheral arterial disease (PAD), previous MI 
and prior stroke or TIA (Table 1). Regarding previous 
cardiovascular treatment, insulin-treated diabetics were 
more frequently treated with aspirin (55.1 vs. 35.6%, p 
= 0.003), angiotensin-converting enzyme (ACE) inhi-
bitors (55.1 vs. 41.2%, p = 0.036), β-blockers (29.0 vs. 
18.3%, p = 0.046), nitrates (29.0 vs. 16.3%, p = 0.015) 
and diuretics (39.1 vs. 25.5%, p = 0.023). However, 
there were no significant differences in the proportion 
of patients receiving statins between the two groups 
(36.2 vs. 28.8, p = 0.222). There were 18.8% patients 
in the insulin-treated group and 39.9% in the non-in-
sulin-treated group on oral antidiabetics (p = 0.001).
There were no statistically significant differences regar-
ding the type of ACS between the two groups (Table 1).
Table 1. Comparison of baseline characteristics between diabetics 





Total number of patients 69 306
Demographic data
Male gender (%) 47/69 (68.1) 205/306 (67.0) 0.858
Mean age (years) (SD) 69.0 ± 10.0 70.0 ± 10.0 0.306
Type of ACS (%)
STEMI 17/69 (24.6) 98/306 (32.0) 0.229
NSTEMI 41/69 (59.4) 164/306 (53.6) 0.380
UA 11/69 (15.9) 44/306 (14.4) 0.740
Cardiovascular risk factors 
Hypertension (%) 57/67 (85.1) 250/295 (84.7) 0.946
Dyslipidemia (%) 57/67 (85.1) 248/293 (84.6) 0.929
Smoking (%) 6/68 (8.8) 32/306 (10.5) 0.687
Stress (%) 14/68 (20.6) 43/306 (14.1) 0.175
Family History of CAD (%) 10/68 (14.7) 33/306 (10.8) 0.359
BMI (Kg/m2) 29.9 ± 6.9 28.5 ± 5.0 0.154
Cardiovascular history (%)
Prior myocardial infarction 22/57 (38.6) 53/262 (20.2) 0.003
Prior PCI 12/62 (19.4) 33/295 (11.2) 0.078
CABG 8/67 (11.9) 17/293 (5.8) 0.105
Previous heart failure 1/25 (4.0) 3/136 (2.2) 0.494
Prior stroke 12/69 (17.4) 28/304 (9.2) 0.047
PVD 9/69 (13.0) 11/304 (3.6) 0.005
STEMI: ST elevation myocardial infarction; NSTEMI: non-ST elevation myocardial infarction; 
UA: unstable angina; BMI: body mass index; PCI: percutaneous coronary intervention; CABG: 
coronary artery bypass graft; PVD: peripheral vascular disease.
For the hemodynamic parameters, the previously 
insulin-treated diabetics were less often in Killip class 
I at admission, presented more frequently LBBB and 
tended to have a lower left ventricular ejection fraction 
(LVEF) (Table 2).
Concerning laboratory parameters, diabetics in the 
insulin-treated group had significantly lower total and 
LDL cholesterol.  In these patients we found signifi-
cantly higher admission glycemia, fasting glycemia and 
glycosylated hemoglobin (HbA1c), significantly lower 
levels of hemoglobin and a trend toward worse glome-
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Table 2. Hemodynamic, electrocardiographic and laboratorial data
Global population Previous insulin No previous insulin p
Hemodynamic data
Heart rate, bpm (SD) 80.0 ± 16.0 81.0 ± 18.0 80.0 ± 16.9 0.569
Systolic blood pressure (mmHg) (SD) 143.0 ± 26.0 145.0 ± 29.0 142.0 ± 26.0 0.485
Diastolic blood pressure (mmHg) (SD) 75.0 ± 14.0 72.0 ± 14.4 75.0 ± 14.0 0.101
Killip Class I at admission (%) 287/368 (78.0) 43/67 (64.2) 244/301 (81.1) 0.003
Killip Class II at admission (%) 70/368 (19.0) 20/67 (29.9) 50/301 (16.6) 0.013
Killip Class III at admission (%) 7/368 (1.9) 3/67 (4.5) 4/301 (1.3) 0.117
Killip Class IV at admission (%) 4/368 (1.1) 1/67 (1.5) 3/301 (1.0) 0.554
LVEF (%) (SD) 50.0 ± 11.0 48.0 ± 12.0 50.0 ± 11.0 0.145
Electrocardiographic data (%)
Synusal rhythm 321/373 (86.1) 59/69 (85.5) 262/304 (86.2) 0.883
Atrial fibrillation 43/373 (11.5) 9/69 (13.0) 34/30 (11.2) 0.662
LBBB 10/373 (2.7) 5/69 (7.2) 5/304 (1.6) 0.022
Laboratorial parameters
Peak TI (mg/L) (SD) 11.0 ± 29.4 10.5 ± 28.4 11.1 ± 30.8 0.764
Peak CK-MB mass (mg/L) (SD) 36.7 ± 110.8 36.0 ± 111.6 37.0 ± 108.0 0.863
Triglycerides (mg/dL) (SD) 175.4 ± 93.0 142.0 ± 72.0 148.0 ± 104.0 0.663
Total cholesterol (mg/dL) (SD) 181.0 ± 64.0 165.0 ± 61.0 183.0 ± 66.0 0.017
LDL cholesterol (mg/dL) (SD) 124.0 ± 46.0 108.0 ± 52.0 126.0 ± 45.0 0.003
HDL cholesterol (mg/dL) (SD) 41.0 ± 11.0 40.0 ± 10.0 42.0 ± 11.0 0.230
Apoprotein B (mg/dL) (SD) 99.0 ± 35.8 91.0 ± 38.5 100.0 ± 35.2 0.077
GFR (mL/min) (SD) 61.7 ± 21.9 56.8 ± 23.7 62.8 ± 21.4 0.083
Admission glycemia (mg/dL) (SD) 169.0 ± 73.0 218.0 ± 108.0 164.0 ± 64.0 < 0.001
Fasting glycemia (mg/dL) (SD) 153.0 ± 58.3 181.0 ± 92.0 146.0 ± 51.0 < 0.001
HbA1c (%) (SD) 6.5 ± 2.0 8.1 ± 2.7 6.4 ± 1.5 0.007
Baseline hemoglobin (g/dL) (SD) 13.6 ± 1.9 13.0 ± 2.2 13.7 ± 1.8 0.016
LVEF: left ventricular ejection fraction; LBBB: left bundle-branch block; TI: troponin I; GFR: glomerular filtration rate; HbA1c: glycosylated hemoglobin. 
Therapeutic approach
Patients underwent an invasive strategy in 53.6% of ca-
ses, with PCI in 117 patients (31.2% of global popula-
tion). In 72 patients (19.2% of the total population and 
62.6% of patients with STEMI), primary angioplasty 
was performed. Of the 201 patients who underwent 
coronary angiography, 29 (14.4%) had anatomically 
normal coronary arteries. Diabetic patients under chro-
nic insulin therapy were less frequently submitted to an 
early invasive approach compared to patients receiving 
oral antidiabetics or without any prior antidiabetic the-
rapy (36.2% vs. 57.5%, p = 0.001) (Table 3).
Regarding coronary anatomy, diabetic patients 
under previous insulin therapy showed more often 
three-vessel disease and left anterior descending artery 
lesions, but these differences were not statistically sig-
nificant (Table 3).
Concerning medical treatment in the first 24 hours 
of hospitalization, most patients in the general popu-
lation were treated with aspirin (95.7%), β-blockers 
(76.5%), ACEI (94.1%), statins (98.1%) and low mo-
lecular weight heparin (LMWH) (97.1%). In 41.6% of 
cases there was the need for diuretics in the first 24 
hours of hospitalization.  There were no statistically 
significant differences in the use of these drugs among 
insulin-treated and non-insulin-treated patients, with 
the exception of diuretics, which were used more fre-
quently in the insulin-treated group (59.4% vs. 37.6%, 
p = 0.001).
At the time of hospital discharge, the most prescri-
bed drugs were, in descending order, statins (95.5%), 
ACE inhibitors (89.1%), aspirin (87.7%) and β-blockers 
(76.5%), with no statistically significant differences be-
tween the two groups.
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Table 3. Catherization lab data
Global population Previous insulin No previous insulin p
Catheterization during hospitalization (%) 201/375 (53.6) 25/69 (36.2) 176/306 (57.5) 0.001
Normal coronaries (%) 29/201 (14.4) 1/25 (4.0) 28/176 (15.9) 0.137
3-vessel disease (%) 62/201 (30.8) 9/25 (36.0) 53/176 (30.1) 0.551
2-vessel disease (%) 39/201 (19.4) 4/25 (16.0) 35/176 (19.9) 0.791
1-vessel disease (%) 68/201 (33.8) 11/25 (44.0) 57/176 (32.4) 0.251
Left main disease (%) 9/201 (4.5) 0/25 (0.0) 9/176 (5.1) 0.605
LAD disease (%) 134/201 (66.7) 20/25 (80.0) 114/176 (64.8) 0.131
Complete revascularization (%) 73/172 (42.4) 10/24 (41.7) 63/148 (42.6) 0.934
Non-revascularizable (%) 55/172 (32) 8/24 (33.3) 47/148 (31.8) 0.878
LAD: left anterior descending coronary artery.
In-hospital outcomes
The mean hospital length of stay was 6.0 ± 3.0 days 
with no statistically significant differences between the 
two groups (5.0 ± 3.0 days in the insulin-treated vs. 6.0 
± 3.0 days in the non-insulin-treated group, p = 0.700).
The pre-specified in-hospital complications rate was 
7.9% and the in-hospital mortality rate 6.4%. There was 
no statistically significant differences in in-hospital com-
plications or in-hospital mortality rates among insulin-
treated and non-insulin-treated patients (10.1% vs. 7.3%, 
p = 0.360 and 10.1% vs. 5.6%, p = 0.174, respectively).
Post-discharge outcomes – 1 year follow-up 
The overall 1-year mortality rate was 11.7% and that of 
MACE 24.5%, without statistically significant differen-





and 32.1% vs. 23.0%, p = 0.146, respectively). The sur-
vival curves showed similar evolution of the two diabetic 
groups during the 1-year follow-up (Figures 1 and 2).
In the Cox regression, the independent predictors 
of overall 1-year mortality were Killip class on admis-
sion > I, total cholesterol > 230 mg/dL and heart rate 
on admission > 101 bpm (Table 4).
Regarding independent predictors of MACE occur-
rence during the first year after the ACS, the multiva-
riate analysis identified the following predictors: LDL 
cholesterol > 113 mg/dL, total cholesterol > 180 mg/dL 
and GFR < 64 mL/min. By contrast, female gender 
was associated with a reduction of 64% in relative risk 
of 1-year MACE (Table 5).
Prior insulin therapy was not found to be neither 
an independent predictor of overall mortality nor of 
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Figure 1. Cumulative survival curves.
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Figure 2. MACE-free survival curves. 
Table 4. Independent predictors of 1-year mortality
HR CI 95% p
HR > 101 bpm 9.24 3.76 – 22.70 < 0.001
Killip class on admission > I 3.71 1.69 – 8.14 0.001
Total cholesterol > 230 mg/dL 3.45 1.53 – 7.75 0.003
Previous insulin therapy 1.75 0.69 – 4.42 0.235
HR: heart rate; bpm: beats per minute.
Table 5. Independent predictors of MACE during the first year after 
the ACS
HR CI 95% p
LDL cholesterol > 113 mg/dL 2.36 1.27 – 4.38 0.007
GFR < 64 mL/min 2.02 1.18 – 3.48 0.011
Total cholesterol > 180 mg/dL 1.83 1.05 – 3.20 0.034
Female gender 0.36 0.19 – 0.70 0.003
Previous insulin therapy 1.64 0.86 – 3.10 0.132
Age > 80 years 2.04 0.98 – 4.24 0.057
ACS: acute coronary syndrome; GFR: glomerular filtration rate.
DISCUSSION
After an ACS, diabetic patients have a considerably po-
orer prognosis in the short and long term than their 
non-diabetic counterparts (3,4,12). The “Euro He-
art Survey on Diabetes and the Heart” showed that 
either previously known DM or newly diagnosed DM 
are associated with a particularly high risk of death and 
cardiovascular events during the first year of clinical 
follow-up (13). On the other hand, hyperglycemia on 
admission has been associated with decreased survi-
val after an ACS, either in diabetics or non-diabetics 
(14,15). Recently, it has been demonstrated that per-
sistent hyperglycemia during hospitalization for ACS 
was a better predictor of in-hospital mortality than 
admission glycemia (16). However, is not completely 
clear whether this decreased survival  is related to the 
development of hyperglycemia in response to stress or 
whether it is related to a worse prior metabolic control 
(15,17). 
Besides the well-known benefit of insulin in the 
metabolic control of diabetic patients, some resear-
chers also propose the existence of a cardioprotective 
action. Recent studies have shown that insulin exerts 
anti-inflammatory and anti-atherogenic effects and im-
proves endothelial function (18-21). 
In the past decade it has become evident that the 
endothelium is not a simple barrier. Nowadays, the en-
dothelium is viewed as a complex organ, with autocrine 
and paracrine function, constituting a first line physio-
logical defense against atherosclerosis (6).
The metabolic abnormalities of diabetes are associa-
ted with endothelial dysfunction. Diabetes induces oxi-
dative and inflammatory stress, vasoconstrictor respon-
ses, thrombotic phenomena and pro-apoptotic effects 
on endothelial cells (22). 
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Insulin appears to exert multiple beneficial effects 
on endothelial cells, platelet and leukocyte function, 
which could be potentially cardioprotective and anti-
atherosclerotic (23-25). 
Several mechanisms have been proposed to explain 
the beneficial effect of insulin on endothelial function: 
1) reduction of serum glucose, triglycerides and free 
fatty acids (which have been associated with endothelial 
dysfunction) (26,27), 2) endothelium-independent va-
sodilatation (which seems to increase significantly with 
insulin therapy), 3) reduction of oxidative stress (28), 
4) stimulation of nitric oxide production in endothelial 
cells (29) and 5) stimulation of endothelial progenitor 
cells via the activation of the receptor for insulin growth 
factor type 1 (IGF-1). In turn, endothelial progenitor 
cells have the ability to improve function of injured ves-
sels by stimulating re-endothelialization and neovascu-
larization (29). 
However, there are some studies that suggest op-
posite effects, stating that insulin therapy is associated 
with increased vascular resistance, ventricular hypertro-
phy and endothelial dysfunction (1,10).
In this work it was found that prior insulin therapy 
did not independently increase the overall mortality or 
the incidence of major adverse cardiac events in the first 
year after an ACS.
In our diabetic population there was a high rate of 
adherence to the pharmacological therapy approach ad-
vocated in acute coronary syndromes. In fact, the use 
of the generality of the drugs recommended in the con-
text of ACS was far superior compared to international 
multicenter studies (13,30). 
An early invasive strategy was used in most patients, 
but less frequently in diabetics under prior insulin the-
rapy.  One possible explanation for this is that some 
insulin-treated diabetics had previously known severe, 
diffuse, non-revascularizable CAD.
The fact that there were no statistically significant 
differences in the type of ACS or in the levels of bio-
chemical markers of myocardial necrosis between the 
two groups, suggests that prior antidiabetic therapy 
does not influence the type of ACS or the extent of 
myocardial necrosis.
The higher prevalence of PAD and of prior stroke/
TIA in the insulin-treated group probably reflects a 
more advanced form of atherosclerosis, involving mul-
tiple arterial territories. However, despite this and the 
lower use of an invasive strategy, the overall mortality 
and the occurrence of MACE during the first year after 
the ACS in insulin-treated patients were similar to that 
of non-insulin-treated patients. Therefore, prior insulin 
therapy did not independently increase the overall mor-
tality or the incidence of major adverse cardiac events in 
the first year after the ACS.
CONCLUSIONS
This work suggests that the worst prognosis of insulin-
treated diabetics reported in other studies is not an inde-
pendent effect of insulin and probably it can be explai-
ned by demographic, clinical or therapeutic differences.
Moreover, it is possible that insulin therapy protects 
diabetic patients from the diabetics patients from the 
expected poor adverse outcome of an advanced athe-
rosclerotic disease. It would therefore be important to 
conduct prospective studies to evaluate the effects of 
insulin on endothelial function, seeking to understand 
the pathophysiological mechanisms involved and to 
investigate the real impact of insulin therapy in CAD 
progression.
Study limitations
The size of the cohort and the number of clinical events 
upon which we base our conclusions are, by compari-
son to the data accumulated in acute coronary syndro-
mes and diabetes, relatively small. However, our cohort 
was unselected in terms of cardiovascular risk factors, 
age, gender and treatment and is in fact a real popula-
tion seen in standard clinical practice. 
We recognize that one important limitation of this 
study is the lack of information about diabetes dura-
tion, which may be significantly longer in previously 
insulin-treated diabetics and could be associated to a 
more diffuse atherosclerotic disease.
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